Status:
COMPLETED
Anti-HIV Activity and Safety of 3 Different Doses of Mifepristone in HIV Infected People
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to determine the anti-HIV activity and safety of 3 different doses of mifepristone (also known as VGX-410 and RU486) in HIV infected people. Hypothesis: Mifepristone will...
Detailed Description
Mifepristone is a potent anti-glucocorticoid compound that effectively inhibits replication of both laboratory and clinical HIV isolates in vitro. This study will evaluate the anti-HIV activity and sa...
Eligibility Criteria
Inclusion
- HIV-1 infected
- CD4 count of 350 cells/mm3 or more within 90 days prior to study entry
- HIV-1 viral load of 2000 copies/ml or more within 90 days prior to study entry
- Willing to use acceptable forms of contraception during the study and for 30 days after stopping study medication
- If currently taking precautionary concomitant medications, must be on stable doses for more than 8 weeks prior to study entry and have no plans to change medications or doses for the duration of the study
- Body weight at least 40 kg (88 lbs) within 90 days prior to study entry
Exclusion
- Antiretroviral treatment (ART) within 16 weeks prior to study entry, or intend to start ART within 60 days after entry
- Adrenal disorders
- History of autoimmune endocrine disease in self or family
- History of active hepatitis B or C
- Current treatment for hepatitis B or C
- Moderate to severe liver disease
- Blood disorders or current anticoagulant therapy
- Prior pituitary tumor, surgery, radiation treatment, or pituitary failure
- Moderate to large goiters or thyroid nodules
- Diabetes mellitus
- Unusual uterine bleeding within 12 months prior to study entry
- Current hormonal contraception or intrauterine (IUD) use, including progesterone-containing vaginal rings
- Pregnancy within 90 days prior to study entry
- Breast-feeding
- Drugs that act as inhibitors or inducers of metabolism by cytochrome P450 3A4
- Systemic corticosteroids or hormonal agents within 90 days prior to study entry
- Any immunomodulator, HIV vaccine, or investigational therapy within 90 days prior to study entry
- Any vaccination within 30 days prior to study entry
- Systemic cytotoxic chemotherapy within 90 days prior to study entry
- History of allergy to mifepristone or the study formulations
- Current drug or alcohol abuse that, in the opinion of the investigator, may interfere with the study
- Any other conditions that may interfere with participant evaluation during the study
- Serious illness requiring systemic treatment or hospitalization. Patients who complete therapy or are clinically stable on therapy for at least 14 days prior to study entry are not excluded.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
August 1 2005
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00099645
End Date
August 1 2005
Last Update
November 1 2021
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Harbor-UCLA Med. Ctr. CRS
Torrance, California, United States, 90502-2052
2
Georgetown University CRS (GU CRS)
Washington D.C., District of Columbia, United States, 20007
3
University of Minnesota, ACTU
Minneapolis, Minnesota, United States, 55455-0392
4
Washington U CRS
St Louis, Missouri, United States, 63108-2138